NCT06485219View on ClinicalTrials.gov

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 14, 2024

Primary Completion Date

November 22, 2025

Study Completion Date

December 22, 2025

Conditions
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)
Interventions
DRUG

11.2 mg/m2 Purinostat Mesylate

Purinostat Mesylate for Injection: Intravenous infusion, The subjects were given intravenous drip injections once on D1, D4, D8 and D11 of each dosing cycle, with a dosing cycle lasting for 21 days. The overall duration of the longest administration period shall not exceed 96 weeks.

DRUG

15 mg/m2 Purinostat Mesylate

Purinostat Mesylate for Injection: Intravenous infusion, The subjects were given intravenous drip injections once on D1, D4, D8 and D11 of each dosing cycle, with a dosing cycle lasting for 21 days. The overall duration of the longest administration period shall not exceed 96 weeks.

Trial Locations (2)

200000

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai

610000

RECRUITING

West China Hospital Sichuan University, Chengdu

All Listed Sponsors
lead

Chengdu Zenitar Biomedical Technology Co., Ltd

INDUSTRY